MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients with Triple Negative or HER2+ MBC

Inclusion Criteria

• •1. Age ≥18
• •2. Triple negative or HER2+ breast cancer (ASCO/CAP guidelines 2018)\*
• •3. MBC, as defined as distant disease outside of the breast and local/regional lymph nodes. Physicians' clinical judgment will be used to determine the possible need for biopsy in confirming a MBC diagnosis. However, biopsy of a metastatic site is not required for pathologic confirmation of stage IV disease.
• •4. Diagnosis of metastatic disease within 12 weeks prior to study enrollment.
• •5. No symptoms of BrM or known asymptomatic BrM at study entry.
• •6. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen may participate.
• •* This will generally be based on the primary cancer but in the event that a metastatic site is biopsied eligibility will be based on the ER, PR and HER2 profile of the metastasis.